← Back to Search

Small Molecule

ATH434 for Multiple System Atrophy

Phase 2
Waitlist Available
Research Sponsored by Alterity Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant has evidence of orthostatic hypotension and/or bladder dysfunction.
Participant has clinical features of parkinsonism.
Must not have
Participant has an unstable medical or psychiatric illness.
Participant is unable to swallow study drug.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new drug to see if it is safe and effective for people with Multiple System Atrophy.

Who is the study for?
This trial is for individuals with Multiple System Atrophy (MSA), showing symptoms like parkinsonism, low blood pressure upon standing, bladder issues, ataxia or abnormal muscle coordination, and certain signs on a neurological exam. They must have MSA biomarkers in their body fluids and MRI scans. People can't join if they can't swallow pills, attend visits, have brain structure issues on MRI, unstable health conditions or other significant neurological disorders.
What is being tested?
The study is testing the safety and effectiveness of a drug called ATH434 in people who are clinically diagnosed with Multiple System Atrophy. It aims to see how well this drug works and what effects it has on patients' bodies.
What are the potential side effects?
While the specific side effects of ATH434 aren't listed here, common types of side effects from drugs treating similar conditions may include nausea, dizziness due to low blood pressure (especially when getting up), digestive problems or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I experience dizziness when standing up or have bladder control issues.
Select...
I show symptoms similar to Parkinson's disease.
Select...
I have coordination issues or muscle weakness.
Select...
My tests show MSA markers in my body fluids and on my MRI.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any unstable medical or mental health conditions.
Select...
I cannot swallow pills.
Select...
I cannot attend the study visits or complete its procedures.
Select...
I have a significant neurological condition, but it's not MSA.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ATH434Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Alterity TherapeuticsLead Sponsor
2 Previous Clinical Trials
92 Total Patients Enrolled
2 Trials studying Multiple System Atrophy
92 Patients Enrolled for Multiple System Atrophy

Media Library

ATH434 (Small Molecule) Clinical Trial Eligibility Overview. Trial Name: NCT05864365 — Phase 2
Multiple System Atrophy Research Study Groups: ATH434
Multiple System Atrophy Clinical Trial 2023: ATH434 Highlights & Side Effects. Trial Name: NCT05864365 — Phase 2
ATH434 (Small Molecule) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05864365 — Phase 2
Multiple System Atrophy Patient Testimony for trial: Trial Name: NCT05864365 — Phase 2
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top